JP Morgan Chase’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.59M | Sell |
287,019
-36,970
| -11% | -$760K | ﹤0.01% | 3060 |
|
|
2026
Q1 | $5.86M | Buy |
323,989
+152,041
| +88% | +$3.03M | ﹤0.01% | 3170 |
|
|
2025
Q4 | $2.84M | Sell |
171,948
-3,073
| -2% | -$51.9K | ﹤0.01% | 3817 |
|
|
2025
Q3 | $2.54M | Sell |
175,021
-16,592
| -9% | -$238K | ﹤0.01% | 3894 |
|
|
2025
Q2 | $2.68M | Buy |
191,613
+3,210
| +2% | +$45.2K | ﹤0.01% | 3688 |
|
|
2025
Q1 | $2.56M | Sell |
188,403
-34,580
| -16% | -$663K | ﹤0.01% | 3687 |
|
|
2024
Q4 | $4.54M | Sell |
222,983
-12,403
| -5% | -$318K | ﹤0.01% | 3449 |
|
|
2024
Q3 | $6.86M | Buy |
235,386
+14,324
| +6% | +$355K | ﹤0.01% | 2952 |
|
|
2024
Q2 | $5.13M | Buy |
221,062
+82,122
| +59% | +$1.58M | ﹤0.01% | 3016 |
|
|
2024
Q1 | $2.85M | Sell |
138,940
-44,376
| -24% | -$834K | ﹤0.01% | 3557 |
|
|
2023
Q4 | $3.93M | Buy |
183,316
+15,352
| +9% | +$304K | ﹤0.01% | 3297 |
|
|
2023
Q3 | $3.47M | Buy |
167,964
+9,972
| +6% | +$253K | ﹤0.01% | 3111 |
|
|
2023
Q2 | $4.66M | Buy |
157,992
+12,005
| +8% | +$338K | ﹤0.01% | 2924 |
|
|
2023
Q1 | $3.36M | Sell |
145,987
-37,989
| -21% | -$1.05M | ﹤0.01% | 3132 |
|
|
2022
Q4 | $5.12M | Buy |
183,976
+75,622
| +70% | +$2.25M | ﹤0.01% | 2791 |
|
|
2022
Q3 | $3.33M | Buy |
108,354
+8,329
| +8% | +$271K | ﹤0.01% | 3075 |
|
|
2022
Q2 | $2.94M | Buy |
100,025
+2,653
| +3% | +$69.5K | ﹤0.01% | 3238 |
|
|
2022
Q1 | $3.13M | Buy |
97,372
+14,227
| +17% | +$490K | ﹤0.01% | 3397 |
|
|
2021
Q4 | $3.71M | Sell |
83,145
-15,365
| -16% | -$728K | ﹤0.01% | 3309 |
|
|
2021
Q3 | $4.97M | Buy |
98,510
+7,630
| +8% | +$430K | ﹤0.01% | 3028 |
|
|
2021
Q2 | $7.13M | Buy |
90,880
+15,699
| +21% | +$971K | ﹤0.01% | 2728 |
|
|
2021
Q1 | $4.29M | Sell |
75,181
-255,912
| -77% | -$17.1M | ﹤0.01% | 3097 |
|
|
2020
Q4 | $27.7M | Buy |
331,093
+22,239
| +7% | +$1.34M | ﹤0.01% | 1395 |
|
|
2020
Q3 | $11.2M | Buy |
308,854
+64,168
| +26% | +$1.93M | ﹤0.01% | 1949 |
|
|
2020
Q2 | $5.92M | Buy |
244,686
+68,843
| +39% | +$1.62M | ﹤0.01% | 2335 |
|
|
2020
Q1 | $3.08M | Buy |
175,843
+98,101
| +126% | +$2.05M | ﹤0.01% | 2641 |
|
|
2019
Q4 | $1.35M | Buy |
77,742
+62,023
| +395% | +$1.03M | ﹤0.01% | 3649 |
|
|
2019
Q3 | $241K | Buy |
15,719
+2,549
| +19% | +$48.7K | ﹤0.01% | 4545 |
|
|
2019
Q2 | $271K | Buy |
13,170
+2,101
| +19% | +$47.1K | ﹤0.01% | 4535 |
|
|
2019
Q1 | $257K | Sell |
11,069
-571
| -5% | -$11.9K | ﹤0.01% | 4516 |
|
|
2018
Q4 | $240K | Buy |
11,640
+1,086
| +10% | +$19.7K | ﹤0.01% | 4504 |
|
|
2018
Q3 | $229K | Buy |
10,554
+7,120
| +207% | +$118K | ﹤0.01% | 4638 |
|
|
2018
Q2 | $52K | Buy |
3,434
+184
| +6% | +$3.47K | ﹤0.01% | 5064 |
|
|
2018
Q1 | $64K | Buy |
+3,250
| New | +$66.8K | ﹤0.01% | 4732 |
|
Other funds holding DNLI
BBA
JP Morgan Chase's DNLI Position: Q2 2026 in Review
JP Morgan Chase reduced its Denali Therapeutics (DNLI) stake by 11% in Q2 2026, selling an estimated $760K and leaving 287,019 shares worth $7.59M. The position accounts for ﹤0.01% of the portfolio, ranked #3060.
JP Morgan Chase first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. The position peaked at $27.7M in Q4 2020. 273 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- JP Morgan Chase held 287,019 shares of Denali Therapeutics worth $7.59M as of Q2 2026.
- JP Morgan Chase sold 36,970 Denali Therapeutics shares in Q2 2026, an estimated $760K.
- Denali Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3060 holding.
- JP Morgan Chase first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
- JP Morgan Chase's Denali Therapeutics position peaked at $27.7M in Q4 2020.
- 273 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.